IRIS
ZAZZI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.710
EU - Europa 20.484
AS - Asia 11.224
SA - Sud America 2.194
Continente sconosciuto - Info sul continente non disponibili 814
AF - Africa 803
OC - Oceania 34
Totale 63.263
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.258
GB - Regno Unito 4.335
RU - Federazione Russa 3.931
CN - Cina 3.441
IT - Italia 3.395
SG - Singapore 3.328
IE - Irlanda 2.544
BR - Brasile 1.762
VN - Vietnam 1.322
SE - Svezia 1.305
DE - Germania 1.241
UA - Ucraina 1.193
FR - Francia 1.142
HK - Hong Kong 1.056
FI - Finlandia 583
KR - Corea 520
ZA - Sudafrica 459
IN - India 398
BD - Bangladesh 242
CA - Canada 215
ES - Italia 179
AR - Argentina 144
NG - Nigeria 124
NL - Olanda 123
IQ - Iraq 120
MX - Messico 120
TR - Turchia 107
JP - Giappone 96
BE - Belgio 91
AT - Austria 82
PK - Pakistan 80
ID - Indonesia 79
PL - Polonia 79
EC - Ecuador 68
CO - Colombia 58
UZ - Uzbekistan 52
VE - Venezuela 50
KE - Kenya 45
SA - Arabia Saudita 43
CL - Cile 40
MY - Malesia 37
CZ - Repubblica Ceca 36
AE - Emirati Arabi Uniti 35
PH - Filippine 33
LT - Lituania 32
MA - Marocco 31
AU - Australia 27
PY - Paraguay 26
JO - Giordania 25
JM - Giamaica 23
EG - Egitto 22
IR - Iran 22
NP - Nepal 21
CI - Costa d'Avorio 18
KZ - Kazakistan 18
PT - Portogallo 18
EE - Estonia 17
ET - Etiopia 17
TH - Thailandia 17
UY - Uruguay 17
CR - Costa Rica 16
GR - Grecia 16
LU - Lussemburgo 16
DZ - Algeria 15
LB - Libano 15
PA - Panama 15
DO - Repubblica Dominicana 14
IL - Israele 14
PE - Perù 14
AL - Albania 13
KG - Kirghizistan 13
SK - Slovacchia (Repubblica Slovacca) 13
BO - Bolivia 12
CH - Svizzera 12
HN - Honduras 12
TN - Tunisia 12
AZ - Azerbaigian 11
DK - Danimarca 11
LV - Lettonia 11
RO - Romania 11
RS - Serbia 11
UG - Uganda 11
EU - Europa 9
BG - Bulgaria 8
BH - Bahrain 8
SN - Senegal 8
TT - Trinidad e Tobago 8
BY - Bielorussia 7
GE - Georgia 7
GT - Guatemala 7
HU - Ungheria 7
LK - Sri Lanka 7
OM - Oman 7
PS - Palestinian Territory 7
TW - Taiwan 7
NI - Nicaragua 6
SY - Repubblica araba siriana 6
AM - Armenia 5
AO - Angola 5
GA - Gabon 5
Totale 62.354
Salva come PNG Salva come JPEG
Città #
Southend 3.724
Dallas 3.050
Fairfield 2.521
Dublin 2.512
Ashburn 2.024
Singapore 1.826
Houston 1.670
Chandler 1.518
San Jose 1.221
Santa Clara 1.176
Woodbridge 1.130
Moscow 1.045
Hong Kong 1.016
Jacksonville 969
Seattle 949
Wilmington 932
Milan 894
Cambridge 851
Ann Arbor 844
Beijing 844
Council Bluffs 765
Siena 610
Hefei 602
Seoul 511
Munich 467
Princeton 433
The Dalles 417
Johannesburg 406
Los Angeles 403
Ho Chi Minh City 391
Rome 346
New York 340
Lauterbourg 304
Nanjing 295
Helsinki 285
Hanoi 277
Menlo Park 222
Boardman 188
Dong Ket 187
San Mateo 181
Columbus 172
São Paulo 163
Buffalo 151
San Diego 139
Shanghai 124
Abuja 119
Bengaluru 114
London 114
Nanchang 113
Málaga 109
Redondo Beach 104
Dearborn 93
Frankfurt am Main 88
Orem 86
Tokyo 82
Brussels 79
Florence 77
Chicago 76
Nuremberg 74
Düsseldorf 72
Chennai 70
Figino 70
Tianjin 67
Montreal 61
Turku 61
Da Nang 60
Phoenix 60
Shenyang 60
Toronto 60
Warsaw 59
San Francisco 58
Atlanta 57
Turin 56
Hebei 51
Rio de Janeiro 51
Vienna 51
Brooklyn 50
Changsha 50
Denver 50
Bologna 49
Hangzhou 49
Naples 48
Lappeenranta 47
Amsterdam 45
Haiphong 45
Manchester 44
Tashkent 43
Baghdad 42
Belo Horizonte 42
Jiaxing 42
Lancaster 42
Mexico City 42
Portsmouth 41
Dhaka 40
Zhengzhou 38
Brasília 37
Jinan 37
Norwalk 37
Guangzhou 36
Kunming 36
Totale 42.479
Salva come PNG Salva come JPEG
Nome #
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 639
Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-infected subjects 634
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 579
Surrogate markers as a guide to evaluate response to antiretroviral therapy 495
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 337
Antigenicity and immunogenicity of the V3 domain of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. AIDS Res Hum Retroviruses 328
A child with vestibular neuritis. Is adenovirus implicated? 324
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 320
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 318
A novel methodology for large-scale phylogeny partition 312
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 312
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 308
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 308
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 307
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 307
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 306
(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity 305
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 303
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 302
Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type 1 nucleoside reverse transcriptase inhibitors 295
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy 294
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 291
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 291
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 288
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 286
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 283
Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples 276
Anticipating policy considerations for a future HIV vaccine: a preliminary study 273
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 272
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 271
Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine and protease inhibitors 270
Decline of Prevalence of Resistance Associated Substitutions to NS3 and NS5A inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018 270
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 269
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 266
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 265
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 265
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 265
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 265
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 265
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 264
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 263
Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy 260
Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy 260
Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8 coinfected patients 258
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 258
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 258
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 257
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 257
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 253
HIV-1 and human myelin proteins share an antigenic determinant 252
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients 252
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 252
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 250
Decline of Prevalence of Resistance Associated Substitutions to NS3 and NS5A inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018 250
An update to the HIV-TRePS system: The development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype 248
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 247
Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection 247
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study 247
Lack of evidence of HHV-8 DNA in blood cells from heart transplant recipients 246
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 246
Advantages of Predicted Phenotypes and Statistical Learning Models in Inferring Virological Response to Antiretroviral Therapy from HIV Genotype 245
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 245
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. 244
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 243
Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union 242
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 241
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 241
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 240
Focal myositis: a polymerase chain reaction analysis for a viral etiology 238
Evidence of differential selection of HIV-1 variants carrying drug resistant mutations in seroconverters 237
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 236
Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression 234
Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors 234
Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo 233
Prevalence of skin allograft discards as a result of serological and molecular microbiological screening in a regional skin bank in Italy 233
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 233
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 233
Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. 232
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 232
The global spread of HIV-1 subtype B epidemic 231
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database 230
Immunoglobulin gene rearrangement analysis in composite Hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells? 230
An update to the HIV-TRePS system: The development of new computational models that do not require a genotype to predict HIV treatment outcomes 228
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA) 224
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy 224
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study 224
Fallimento virologico precoce con selezione rapida di farmacoresistenza in un paziente con HCV genotipo 1, trattato con peginterferon, ribavirina e telaprevir 223
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 222
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 221
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 220
European guidelines on the clinical management of HIV-1 tropism testing 220
Neuronal intranuclear inclusion disease: polymerase chain reaction and ultrastructural study of rectal biopsy specimen in a new case 218
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 218
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 217
Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 plasma RNA 216
Evaluation of cell-free and cell-associated peripheral blood HIV-1 RNA response to antiretroviral therapy 215
Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy 213
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 212
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 209
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 208
Totale 27.028
Salva come PNG Salva come JPEG
Categoria #
all - tutte 199.150
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 199.150
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.209 0 0 268 397 198 147 209 173 301 396 360 760
2022/20235.234 312 514 617 725 505 1.030 148 432 491 158 201 101
2023/20243.724 157 98 315 210 78 1.083 1.277 103 18 63 82 240
2024/20258.759 189 400 838 425 1.002 552 376 562 811 436 910 2.258
2025/202620.929 1.649 2.757 2.628 2.291 3.804 761 2.242 829 714 1.075 572 1.607
2026/20272.467 912 632 923 0 0 0 0 0 0 0 0 0
Totale 63.263